TrialBritish journal of cancer2014

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.

E Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.